摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-[1,3]oxazolo[4,5-b]pyrazine

中文名称
——
中文别名
——
英文名称
2-Methyl-[1,3]oxazolo[4,5-b]pyrazine
英文别名
——
2-Methyl-[1,3]oxazolo[4,5-b]pyrazine化学式
CAS
——
化学式
C6H5N3O
mdl
——
分子量
135.12
InChiKey
PZCYKHCVKDMTDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    申请人:BlinkBio, Inc.
    公开号:US20170202970A1
    公开(公告)日:2017-07-20
    Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    本文描述了基于硅的共轭物,能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心,一个或多个可选的催化基团,一个定位基团,允许共轭物在靶细胞或组织内积累,一个或多个有效载荷基团(例如,治疗剂或成像剂),以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
  • Polymerisation Catalyst
    申请人:Gibson Vernon Charles
    公开号:US20080200625A1
    公开(公告)日:2008-08-21
    A polymerisation catalyst comprising (1) a transition metal compound of Formula (A), and optionally (2) an activator, wherein Z is 5-membered heterocyclic containing carbon, nitrogen and at least one other selected from nitrogen, sulphur and oxygen, the remaining atoms in the ring being nitrogen and carbon; M is a metal from Group 3 to 11 or a lanthanide metal; E 1 and E 2 are divalent hydrocarbon, heterocyclic or heterosubstituted derivatives of these; D 1 and D 2 are donor atoms or groups; X is an anionic group, L is a neutral donor group; n=m=zero or 1; y and z are zero or integers so that X and L satisfy the valency/oxidation state of M, characterized in that the complex contains at least one polymerisable olefinic double bond which is present in, or substituent to, at least one of the atoms, groups or ligands represented by Z, E, D and L. The catalyst binds to the forming polymer providing product with good particle morphology.
    一种聚合催化剂,包括(1)式(A)的过渡金属化合物,以及可选的(2)活化剂,其中Z是含有碳、氮和至少一种从氮、硫和氧中选择的其他元素的5元杂环,环中其余原子为氮和碳;M是3到11组或镧系金属中的金属;E1和E2是二价的碳氢化合物、杂环或这些的杂基衍生物;D1和D2是给体原子或基团;X是负离子基团,L是中性给体基团;n=m=0或1;y和z为零或整数,以使X和L满足M的化合价/氧化态,其特征在于该配合物至少含有一个聚合性烯烃双键,该双键存在于Z、E、D和L所代表的原子、基团或配体中的至少一个中或代替其中之一。催化剂与形成的聚合物结合,提供具有良好颗粒形态的产品。
  • Diene Polymerisation
    申请人:Jacobsen Grant Berent
    公开号:US20100022724A1
    公开(公告)日:2010-01-28
    A process for producing homopolymers or copolymers of conjugated dienes comprising contacting monomeric material comprising at least one conjugated diene with a catalyst system comprising two or more different transition metal compounds and optionally one or more activators. Preferred transition metal compounds are based on cobalt and chromium, especially complexes thereof having benzimidazole ligands.
    生产共轭二烯的同聚物或共聚物的过程,包括将至少含有一种共轭二烯的单体材料与催化剂体系接触,所述催化剂体系包括两种或更多不同的过渡金属化合物和可选的一个或多个活化剂。首选的过渡金属化合物基于钴和铬,特别是具有苯并咪唑配体的配合物。
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    申请人:Boger Dale L.
    公开号:US20090270421A1
    公开(公告)日:2009-10-29
    Potent inhibitors of fatty acid amide hydrolase (FAAH) are constructed having K i 's below 200 pM and activities 10 2 -10 3 times more potent than the corresponding trifluoromethyl ketones. The potent inhibitors combine several features, viz.: 1.) an α-keto heterocylic head group; 2.) a hydrocarbon linkage unit employing an optimal C12-C8 chain length; and 3.) a phenyl or other π-unsaturation corresponding to the arachidonyl Δ 8,9 /Δ 11,12 and/or oleyl Δ 9,10 positions. A preferred α-keto heterocylic head group is α-keto N4 oxazolopyridine, with incorporation of a second weakly basic nitrogen. Fatty acid amide hydrolase is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors).
    具有Ki值低于200 pM的脂肪酸酰胺水解酶(FAAH)的强效抑制剂被构建出来,其活性比相应的三氟甲基酮高102-103倍。这些强效抑制剂结合了几个特征,即:1)α-酮杂环头基团;2)使用最佳C12-C8链长的烃链连接单元;和3)与花生四烯酸Δ8,9/Δ11,12和/或油酸Δ9,10位置相对应的苯基或其他π-不饱和度。首选的α-酮杂环头基团是α-酮N4噁唑吡啶,并结合第二个弱碱性氮。脂肪酸酰胺水解酶是一种酶,负责降解油酰胺(一种内源性诱导睡眠的脂质)和阿那达胺(一种内源性的大麻素受体配体)。
  • Useful indole compounds
    申请人:Bartolini Wilmin
    公开号:US20070203209A1
    公开(公告)日:2007-08-30
    Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.
    本文描述了具有多种活性的吲哚类化合物,包括CRTH2的吲哚类化合物。这些化合物可用于治疗哮喘、神经病性疼痛、过敏性鼻炎和其他疾病。
查看更多

同类化合物

5-羟基-异恶唑[4,5-B]吡嗪-3-甲酸甲酯 5-氯吡嗪并[2,3-d]异�f唑 3-氨基异噁唑并[4,5-b]吡嗪 (1S,2R,19R,22S,34S,37R,40R,52R)-2-{[(2R,3R,4R,5S,6R)-3-(乙酰基氨基)-4,5-二羟基-6-(羟甲基)四氢-2H-吡喃-2-基]氧代}-22-氨基-5,15-二氯-64-({(2S,3R,4R,5S,6R)-4,5-二羟基-6-(羟甲基)-3-[(9-甲基癸酰)氨基]四氢-2H-吡喃-2 3-Methyl-6-nitro-isoxazolo<4,5-b>pyrazin-7-oxid 4-(3-(3-Methoxybenzyl)-2-oxo-2,3-dihydrooxazolo[5,4-b]pyrazin-5-yl)-N-methyl benzamide 5-Chloroisoxazolo[4,5-b]pyrazin-3-amine 5-Methyl-[1,3]oxazolo[4,5-b]pyrazin-2-amine 3-Tert-butyl-[1,2]oxazolo[4,5-b]pyrazine 5-Bromoisoxazolo[4,5-b]pyrazin-3-amine 4-[[3-[(3-Methoxyphenyl)methyl]-2-oxo-[1,3]oxazolo[4,5-b]pyrazin-5-yl]methyl]benzamide 2-([1,3]Oxazolo[4,5-b]pyrazin-5-ylamino)ethanesulfonamide 5,6-Dimethyl-[1,2]oxazolo[4,5-b]pyrazine Butyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Ethyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 5-Fluoro-isoxazolo[4,5-b]pyrazine-3-carboxylic acid methyl ester Hexyl 5-fluoro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Ethyl 5-fluoro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 2-Methylpropyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 2,2-Dimethylpropyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Hexyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 2-Methylpropyl 5-fluoro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 5-chloro-N,N-diethyl-[1,2]oxazolo[4,5-b]pyrazine-3-carboxamide (5-Chloro-[1,2]oxazolo[4,5-b]pyrazin-3-yl)-pyrrolidin-1-ylmethanone Butyl 5-fluoro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Cyclohexyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Propan-2-yl 5-fluoro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Propan-2-yl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate Propyl 5-chloro-[1,2]oxazolo[4,5-b]pyrazine-3-carboxylate 6-Methyl-[1,2]oxazolo[4,5-b]pyrazine 2-Methyl-[1,3]oxazolo[4,5-b]pyrazine 5-Methyl-[1,3]oxazolo[4,5-b]pyrazine 6-Methyl-[1,3]oxazolo[4,5-b]pyrazine 5-Methyl-[1,2]oxazolo[4,5-b]pyrazine 3-Methylisoxazolo<4,5-b>pyridin